{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T16:43:27Z","timestamp":1775234607968,"version":"3.50.1"},"reference-count":72,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,5,12]],"date-time":"2020-05-12T00:00:00Z","timestamp":1589241600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"DOI":"10.3389\/fonc.2020.00620","type":"journal-article","created":{"date-parts":[[2020,5,12]],"date-time":"2020-05-12T05:48:16Z","timestamp":1589262496000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Biochemical Predictors of Response to Neoadjuvant Therapy in Pancreatic Ductal Adenocarcinoma"],"prefix":"10.3389","volume":"10","author":[{"given":"Seifeldin","family":"Awad","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmad M.","family":"Alkashash","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magi","family":"Amin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samantha J.","family":"Baker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. Bart","family":"Rose","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2020,5,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21551","article-title":"Cancer statistics, 2019","volume":"69","author":"Siegel","year":"2019","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1016\/j.diii.2016.07.011","article-title":"Radiological evaluation of response to neoadjuvant treatment in pancreatic cancer","volume":"97","author":"Cassinotto","year":"2016","journal-title":"Diagn Interv Imaging"},{"key":"B3","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1097\/SLA.0000000000000867","article-title":"Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer","volume":"261","author":"Ferrone","year":"2015","journal-title":"Ann Surg"},{"key":"B4","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1097\/SLA.0000000000002957","article-title":"A phase II clinical trial of molecular profiled neoadjuvant therapy for localized pancreatic ductal adenocarcinoma","volume":"268","author":"Tsai","year":"2018","journal-title":"Ann Surg"},{"key":"B5","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1097\/COH.0b013e32833ed177","article-title":"What are biomarkers?","volume":"5","author":"Strimbu","year":"2010","journal-title":"Curr Opin HIV AIDS"},{"key":"B6","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrd1287","article-title":"Oxaliplatin","volume":"3","author":"Graham","year":"2004","journal-title":"Nat Rev Drug Discov"},{"key":"B7","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1158\/1535-7163.MCT-18-0899","article-title":"CYR61\/CCN1 regulates dCK and CTGF and causes gemcitabine-resistant phenotype in pancreatic ductal adenocarcinoma","volume":"18","author":"Maity","year":"2019","journal-title":"Mol Cancer Ther"},{"key":"B8","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1002\/bjs.10482","article-title":"Immunohistochemical hENT1 expression as a prognostic biomarker in patients with resected pancreatic ductal adenocarcinoma undergoing adjuvant gemcitabine-based chemotherapy","volume":"104","author":"Bird","year":"2017","journal-title":"Br J Surg"},{"key":"B9","first-page":"473","article-title":"Gemcitabine enhances OSI-027 cytotoxicity by upregulation of miR-663a in pancreatic ductal adenocarcinoma cells","volume":"11","author":"Huang","year":"2019","journal-title":"Am J Transl Res"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1245\/s10434-014-3486-z","article-title":"Extended neoadjuvant chemotherapy for borderline resectable pancreatic cancer demonstrates promising postoperative outcomes and survival","volume":"21","author":"Rose","year":"2014","journal-title":"Ann Surg Oncol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine","volume":"369","author":"Von Hoff","year":"2013","journal-title":"N Engl J Med"},{"key":"B12","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s12957-016-0813-9","article-title":"Gemcitabine plus cisplatin versus gemcitabine alone in the treatment of pancreatic cancer: a meta-analysis","volume":"14","author":"Ouyang","year":"2016","journal-title":"World J Surg Oncol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/j.bbrc.2013.06.103","article-title":"Cisplatin-induced non-apoptotic death of pancreatic cancer cells requires mitochondrial cyclophilin-D-p53 signaling","volume":"437","author":"Chen","year":"2013","journal-title":"Biochem Biophys Res Commun"},{"key":"B14","first-page":"521","article-title":"Synergistic interaction between cisplatin and gemcitabine in vitro","volume":"2","author":"Bergman","year":"1996","journal-title":"Clin Cancer Res"},{"key":"B15","first-page":"72","article-title":"Interaction between cisplatin and gemcitabine in vitro and in vivo","volume":"22","author":"Peters","year":"1995","journal-title":"Semin Oncol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1177\/1756283X13478680","article-title":"Pancreatic cancer: why is it so hard to treat?","volume":"6","author":"Oberstein","year":"2013","journal-title":"Ther Adv Gastroenterol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/cgt.2016.71","article-title":"Acquired resistance of pancreatic cancer cells to cisplatin is multifactorial with cell context-dependent involvement of resistance genes","volume":"23","author":"Mezencev","year":"2016","journal-title":"Cancer Gene Ther"},{"key":"B18","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3390\/biology6010016","article-title":"Selectin ligands Sialyl-Lewis a and Sialyl-Lewis x in gastrointestinal cancers","author":"Trinchera","year":"2017","journal-title":"Biology"},{"key":"B19","unstructured":"HermanJHJ KoAH NCCN Guidelines Panel Disclosures2015"},{"key":"B20","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1111\/hpb.12448","article-title":"Pre-treatment carbohydrate antigen 19-9 does not predict the response to neoadjuvant therapy in patients with localized pancreatic cancer","volume":"17","author":"Aldakkak","year":"2015","journal-title":"HPB"},{"key":"B21","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.jamcollsurg.2016.02.009","article-title":"Carbohydrate Antigen 19-9 elevation in anatomically resectable, early stage pancreatic cancer is independently associated with decreased overall survival and an indication for neoadjuvant therapy: a national cancer database study","volume":"223","author":"Bergquist","year":"2016","journal-title":"J Am Coll Surg"},{"key":"B22","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1111\/hpb.12154","article-title":"Serum carbohydrate antigen 19-9 represents a marker of response to neoadjuvant therapy in patients with borderline resectable pancreatic cancer","volume":"16","author":"Tzeng","year":"2014","journal-title":"HPB"},{"key":"B23","doi-asserted-by":"publisher","first-page":"3512","DOI":"10.1245\/s10434-008-0134-5","article-title":"Preoperative CA 19-9 and the yield of staging laparoscopy in patients with radiographically resectable pancreatic adenocarcinoma","volume":"15","author":"Maithel","year":"2008","journal-title":"Ann Surg Oncol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1016\/j.ijrobp.2008.06.1483","article-title":"CA 19-9 as a predictor for response and survival in advanced pancreatic cancer patients treated with chemoradiotherapy","volume":"73","author":"Koom","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1038\/sj.bjc.6601263","article-title":"Prognostic value of CA 19-9 levels in patients with inoperable adenocarcinoma of the pancreas treated with gemcitabine","volume":"89","author":"Ziske","year":"2003","journal-title":"Br J Cancer"},{"key":"B26","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1080\/0284186X.2016.1256497","article-title":"Predictors and survival for pathologic tumor response grade in borderline resectable and locally advanced pancreatic cancer treated with induction chemotherapy and neoadjuvant stereotactic body radiotherapy","volume":"56","author":"Mellon","year":"2017","journal-title":"Acta Oncol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1159\/000494382","article-title":"Predictive early recurrence factors of preoperative clinicophysiological findings in pancreatic cancer","volume":"59","author":"Suzuki","year":"2018","journal-title":"Eur Surg Res"},{"key":"B28","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1177\/000313481808400130","article-title":"Span-1 and CA19-9 as predictors of early recurrence and lymph node metastasis for patients with invasive pancreatic cancer after pancreatectomy","volume":"84","author":"Shimizu","year":"2018","journal-title":"Am Surg"},{"key":"B29","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1007\/s13193-011-0042-1","article-title":"Serum CA 19-9 as a biomarker for pancreatic cancer-A comprehensive review","volume":"2","author":"Ballehaninna","year":"2011","journal-title":"Indian J Surg Oncol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"340","DOI":"10.2174\/156652413805076876","article-title":"The clinical utility of CA 19-9 in pancreatic adenocarcinoma: diagnostic and prognostic updates","volume":"13","author":"Poruk","year":"2013","journal-title":"Curr Mol Med"},{"key":"B31","first-page":"595","article-title":"Carcinoembryonic antigen (CEA) levels in hookah smokers, cigarette smokers and non-smokers","volume":"57","author":"Sajid","year":"2007","journal-title":"J Pak Med Assoc"},{"key":"B32","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/1476-4598-5-50","article-title":"Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors","volume":"5","author":"Gubbels","year":"2006","journal-title":"Mol Cancer"},{"key":"B33","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.pan.2015.10.008","article-title":"CA-125, but not galectin-3, complements CA 19-9 for discriminating ductal adenocarcinoma versus non-malignant pancreatic diseases","volume":"16","author":"Coppin","year":"2016","journal-title":"Pancreatology"},{"key":"B34","doi-asserted-by":"publisher","first-page":"6569","DOI":"10.7314\/APJCP.2015.16.15.6569","article-title":"Applicative value of serum CA19-9, CEA, CA125 and CA242 in diagnosis and prognosis for patients with pancreatic cancer treated by concurrent chemoradiotherapy","volume":"16","author":"Gu","year":"2015","journal-title":"Asian Pac J Cancer Prev"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1038\/bjc.2013.158","article-title":"Cytokeratin 19-fragments (CYFRA 21\u20131) as a novel serum biomarker for response and survival in patients with advanced pancreatic cancer","volume":"108","author":"Boeck","year":"2013","journal-title":"Br J Cancer"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1002\/1097-0142(19900401)65:7<1557::AID-CNCR28206507183.0.CO;2-W","article-title":"Usefulness of a new tumor marker, Span-1, for the diagnosis of pancreatic cancer","volume":"65","author":"Kiriyama","year":"1990","journal-title":"Cancer"},{"key":"B37","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.hpb.2016.12.007","article-title":"Preoperative fecal elastase-1 is a useful prognostic marker following curative resection of pancreatic cancer","volume":"19","author":"Lim","year":"2017","journal-title":"HPB"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1097\/MPA.0b013e3182a23ae4","article-title":"A meta-analysis of gemcitabine biomarkers in patients with pancreaticobiliary cancers","volume":"42","author":"Wei","year":"2013","journal-title":"Pancreas"},{"key":"B39","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3390\/cancers9110157","article-title":"Pancreatic cancer chemoresistance to gemcitabine","author":"Amrutkar","year":"2017","journal-title":"Cancers"},{"key":"B40","doi-asserted-by":"publisher","first-page":"3761","DOI":"10.1158\/0008-5472.CAN-03-3363","article-title":"An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines","volume":"64","author":"Davidson","year":"2004","journal-title":"Cancer Res"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1002\/ijc.22390","article-title":"Involvement of ribonucleotide reductase M1 subunit overexpression in gemcitabine resistance of human pancreatic cancer","volume":"120","author":"Nakahira","year":"2007","journal-title":"Int J Cancer"},{"key":"B42","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.lungcan.2010.02.005","article-title":"The immunohistochemical overexpression of ribonucleotide reductase regulatory subunit M1 (RRM1) protein is a predictor of shorter survival to gemcitabine-based chemotherapy in advanced non-small cell lung cancer (NSCLC)","volume":"70","author":"Lee","year":"2010","journal-title":"Lung Cancer"},{"key":"B43","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1158\/2159-8290.CD-11-0242","article-title":"nab-Paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer","volume":"2","author":"Frese","year":"2012","journal-title":"Cancer Discov"},{"key":"B44","doi-asserted-by":"publisher","first-page":"3812","DOI":"10.1038\/onc.2013.357","article-title":"Macrophages mediate gemcitabine resistance of pancreatic adenocarcinoma by upregulating cytidine deaminase","volume":"33","author":"Weizman","year":"2014","journal-title":"Oncogene"},{"key":"B45","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.gene.2015.01.010","article-title":"Cytidine deaminase polymorphism predicts toxicity of gemcitabine-based chemotherapy","volume":"559","author":"Ding","year":"2015","journal-title":"Gene"},{"key":"B46","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1097\/01.sla.0000143300.49878.51","article-title":"Clinical significance of dihydropyrimidine dehydrogenase in adjuvant 5-fluorouracil liver perfusion chemotherapy for pancreatic cancer","volume":"240","author":"Nakayama","year":"2004","journal-title":"Ann Surg"},{"key":"B47","first-page":"2997","article-title":"Clinical application of immunoreactivity of dihydropyrimidine dehydrogenase (DPD) in gastric scirrhous carcinoma treated with S-1, a new DPD inhibitory fluoropyrimidine","volume":"25","author":"Shimizu","year":"2005","journal-title":"Anticancer Res"},{"key":"B48","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/S0140-6736(16)30583-9","article-title":"Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01)","volume":"388","author":"Uesaka","year":"2016","journal-title":"Lancet"},{"key":"B49","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1097\/MPA.0b013e3181dec17d","article-title":"Contribution of thymidylate synthase to gemcitabine therapy for advanced pancreatic cancer","volume":"39","author":"Komori","year":"2010","journal-title":"Pancreas"},{"key":"B50","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s00384-006-0111-z","article-title":"Thymidylate synthase expression in resectable and unresectable pancreatic cancer: role as predictive or prognostic marker?","volume":"22","author":"Formentini","year":"2007","journal-title":"Int J Colorectal Dis"},{"key":"B51","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1124\/dmd.110.033613","article-title":"Drug efflux transporter multidrug resistance-associated protein 5 affects sensitivity of pancreatic cancer cell lines to the nucleoside anticancer drug 5-fluorouracil","volume":"39","author":"Nambaru","year":"2011","journal-title":"Drug Metab Dispos"},{"key":"B52","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1001\/jama.297.17.1901","article-title":"MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis","volume":"297","author":"Bloomston","year":"2007","journal-title":"JAMA"},{"key":"B53","doi-asserted-by":"publisher","first-page":"2699","DOI":"10.1245\/s10434-011-1610-x","article-title":"Differential expression of ERCC1 in pancreas adenocarcinoma: high tumor expression is associated with earlier recurrence and shortened survival after resection","volume":"18","author":"Maithel","year":"2011","journal-title":"Ann Surg Oncol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1080\/15257770.2014.891741","article-title":"miR-211 modulates gemcitabine activity through downregulation of ribonucleotide reductase and inhibits the invasive behavior of pancreatic cancer cells","volume":"33","author":"Maftouh","year":"2014","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"B55","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1158\/1078-0432.CCR-07-2238","article-title":"Platinum resistance: the role of DNA repair pathways","volume":"14","author":"Martin","year":"2008","journal-title":"Clin Cancer Res"},{"key":"B56","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.1002\/ijc.30650","article-title":"Analysis of ctDNA to predict prognosis and monitor treatment responses in metastatic pancreatic cancer patients","volume":"140","author":"Cheng","year":"2017","journal-title":"Int J Cancer"},{"key":"B57","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/j.molonc.2015.11.012","article-title":"Clinical relevance of circulating KRAS mutated DNA in plasma from patients with advanced pancreatic cancer","volume":"10","author":"Tjensvoll","year":"2016","journal-title":"Mol Oncol"},{"key":"B58","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.cancergen.2017.08.006","article-title":"Circulating cell-free DNA mutation patterns in early and late stage colon and pancreatic cancer","volume":"9","author":"Vietsch","year":"2017","journal-title":"Cancer Genet"},{"key":"B59","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1097\/SLA.0000000000001600","article-title":"Circulating tumor cell phenotype predicts recurrence and survival in pancreatic adenocarcinoma","volume":"264","author":"Poruk","year":"2016","journal-title":"Ann Surg"},{"key":"B60","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1097\/SLA.0000000000002925","article-title":"Circulating tumor cells dynamics in pancreatic adenocarcinoma correlate with disease status: results of the prospective CLUSTER study","volume":"268","author":"Gemenetzis","year":"2018","journal-title":"Ann Surg"},{"key":"B61","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.tranon.2015.11.007","article-title":"Prognostic value of SMAD4 in pancreatic cancer: a meta-analysis","volume":"9","author":"Shugang","year":"2016","journal-title":"Transl Oncol"},{"key":"B62","doi-asserted-by":"publisher","first-page":"1806","DOI":"10.1200\/JCO.2008.17.7188","article-title":"DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer","volume":"27","author":"Iacobuzio-Donahue","year":"2009","journal-title":"J Clin Oncol"},{"key":"B63","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1093\/jnci\/djv132","article-title":"Carboxylesterase 2 as a determinant of response to irinotecan and neoadjuvant FOLFIRINOX therapy in pancreatic ductal adenocarcinoma","author":"Capello","year":"2015","journal-title":"J Natl Cancer Inst"},{"key":"B64","doi-asserted-by":"publisher","first-page":"7077","DOI":"10.1038\/sj.onc.1205857","article-title":"Transcriptional upregulation of SPARC, in response to c-Jun overexpression, contributes to increased motility and invasion of MCF7 breast cancer cells","volume":"21","author":"Briggs","year":"2002","journal-title":"Oncogene"},{"key":"B65","doi-asserted-by":"publisher","first-page":"4548","DOI":"10.1200\/JCO.2011.36.5742","article-title":"Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I\/II trial","volume":"29","author":"Von Hoff","year":"2011","journal-title":"J Clin Oncol"},{"key":"B66","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.3109\/00365521.2015.1024281","article-title":"The role of SPARC expression in pancreatic cancer progression and patient survival","volume":"50","author":"Gundewar","year":"2015","journal-title":"Scand J Gastroenterol"},{"key":"B67","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1111\/ans.12399","article-title":"Prognostic significance of epidermal growth factor receptor overexpression in pancreas cancer and nodal metastasis","volume":"85","author":"Perini","year":"2015","journal-title":"ANZ J Surg"},{"key":"B68","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1200\/JCO.2006.07.9525","article-title":"Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group","volume":"25","author":"Moore","year":"2007","journal-title":"J Clin Oncol"},{"key":"B69","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1001\/jama.2016.4324","article-title":"Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without Erlotinib: the LAP07 randomized clinical trial","volume":"315","author":"Hammel","year":"2016","journal-title":"JAMA"},{"key":"B70","doi-asserted-by":"publisher","first-page":"165","DOI":"10.4161\/cbt.12.3.16292","article-title":"Complete remission, in BRCA2 mutation carrier with metastatic pancreatic adenocarcinoma, treated with cisplatin based therapy","volume":"12","author":"Sonnenblick","year":"2011","journal-title":"Cancer Biol Ther"},{"key":"B71","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1002\/cncr.31218","article-title":"Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: Germline BRCA mutation carriers and wild-type BRCA pancreatic ductal adenocarcinoma","volume":"124","author":"O'Reilly","year":"2018","journal-title":"Cancer"},{"key":"B72","doi-asserted-by":"publisher","first-page":"340","DOI":"10.6092\/1590-8577\/2690","article-title":"PARP-inhibitors in BRCA-associated pancreatic cancer","volume":"15","author":"Bhalla","year":"2014","journal-title":"JOP"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2020.00620\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,13]],"date-time":"2021-03-13T22:00:21Z","timestamp":1615672821000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2020.00620\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,12]]},"references-count":72,"alternative-id":["10.3389\/fonc.2020.00620"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2020.00620","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,12]]},"article-number":"620"}}